Pfizer said that Axitinib is an oral and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2 and 3.
Pfizer Oncology Business Unit Clinical Development senior vice president Mace Rothenberg said that it is gratifying that in this trial Axitinib provided significant benefit to patients with advanced RCC whose disease had progressed after 1st-line therapy.
"These results provide insight into the potential value of Axitinib as part of a sequential treatment approach in patients with advanced RCC, Rothenberg said.
"We will work with health authorities to determine possible filing options for Axitinib for use in patients with advanced RCC."